Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 19/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817153 | 0.85 | MKNK1 (0.49) | FYNMKNK1FGFR1 | |
| Ammonia Solution, Strong SCHEMBL2817518 | 0.83 | ADORA3 (0.50) | FYNMKNK1 | |
| SCHEMBL11483436 | 0.82 | ADORA3 (0.49) | FYNMKNK1 | |
| SCHEMBL2814411 | 0.82 | MAPT (0.40) | FYNFGFR1 | |
| SCHEMBL2816016 | 0.78 | TYMS (0.47) | FYNMKNK1FGFR1 | |
| SCHEMBL2817723 | 0.77 | FYN (0.45) | FYNMKNK1FGFR1 | |
| SCHEMBL2815160 | 0.75 | IKBKB (0.47) | FYNMKNK1 | |
| SCHEMBL2815424 | 0.75 | IKBKB (0.47) | FYNMKNK1 | |
| SCHEMBL2816945 | 0.72 | FYN (0.50) | FYNFGFR1 | |
| SCHEMBL12403582 | 0.72 | MDM2 (0.51) | FYNFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | claimed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | claimed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | FYN 3385/4885MKNK1 307/4885FGFR1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.